New and converging technology continue to push the bounds of what is patentable. Business method patents may be patent-eligible, but what separates a patentable method from a mere abstract idea or phenomenon of nature? How has Bilski and its progeny impacted your patent procurement and enforcement strategy? This panel will examine the debate between having a competitive advantage vs. the greater good and how the following issues are affecting your business:
- Did the Supreme Court provide sufficient guidance to lower courts on the appropriate test for patent-eligibility? Is the “machine or transformation” test appropriate for all technologies?
- The impact of Bilski on procurement and enforcement strategies:
- How to draft patent claims most likely to survive a § 101 challenge
- How the Supreme Court’s decision will impact litigation tactics
- How to draft patent claims most likely to survive a § 101 challenge
- The repercussions for innovation
- Revised approaches for protecting proprietary methods
Panelists:
- Paul Hunter, Vice Chair, Electronics Practice
- Steve Rizzi, Chair, China Practice
- James Smith, Associate GC & Chief IP Officer, Baxter Healthcare Corporation
- E. Earle Thompson, Chief Intellectual Property Counsel, SanDisk Corporation
- Mialeeka Williams, Counsel, The Coca-Cola Company
- Michael Whitehead, Chief Counsel, Intellectual Property, The Lincoln Electric Company
Related Insights
21 May 2025
Tariff & International Trade Resource
What Every Multinational Company Should Know About … Customs Enforcement and False Claims Act Risks (Part III)
We complete the series on “Customs Enforcement and False Claims Act Risks” with Part III, which focuses on preparing for the most common FCA risks arising from improper management of import operations.
02 June 2025
Events
Biotech Panel Discussion & Happy Hour
Join Foley & Lardner LLP along with Biotech XYZ for an engaging evening event featuring a dynamic panel discussion and a lively happy hour.
03 June 2025
Events
Biotech Breakfast + Office Hours
Join Foley & Lardner LLP along with Biotech XYZ for Phase Capitals’ flagship networking biotech breakfast and office hours with Q&A sessions.